Discovery - University of Dundee - Online Publications

Library & Learning Centre

6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane

6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor

Research output: Contribution to journalArticle

View graph of relations

Authors

  • Fabrizio Micheli
  • Paolo Cavanni
  • Daniele Andreotti
  • Roberto Arban
  • Roberto Benedetti
  • Barbara Bertani
  • Michela Bettati
  • Letizia Bettelini
  • Giorgio Bonanomi
  • Simone Braggio
  • Renzo Carletti
  • Anna Checchia
  • Mauro Corsi
  • Elettra Fazzolari
  • Stefano Fontana
  • Carla Marchioro
  • Emilio Merlo-Pich
  • Michele Negri
  • Beatrice Oliosi
  • Emiliangelo Ratti
  • And 11 others
  • Kevin D. Read
  • Maja Roscic
  • Ilaria Sartori
  • Simone Spada
  • Giovanna Tedesco
  • Luca Tarsi
  • Silvia Terreni
  • Filippo Visentini
  • Alessandro Zocchi
  • Laura Zonzini
  • Romano Di Fabio

Research units

Info

Original languageEnglish
Pages4989-5001
Number of pages13
JournalJournal of Medicinal Chemistry
Journal publication date8 Jul 2010
Volume53
Issue13
DOIs
StatePublished

Abstract

A pharmacophore model for triple reuptake inhibitors and the new class of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes were recently reported. Further investigation in this area led to the identification of a new series of potent and selective triple reuptake inhibitors endowed with good developability characteristics. Excellent bioavailability and brain penetration are associated with this series of 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptanes together with high in vitro potency and selectivity at SERT, NET, and DAT. In vivo microdialysis experiments in different animal models and receptor occupancy studies in rat confirmed that derivative 17 showed an appropriate profile to further progression of the compound.

Documents

Library & Learning Centre

Contact | Accessibility | Policy